PCA3 como biomarcador de segunda línea en un programa de screening oportunista prospectivo, aleatorizado y controlado

Rubio‐Briones, J.; Casanova, J.; Martínez, Fernando; Domínguez-Escrig, José; Fernández-Serra, Antonio; Dumont, R.; Ramírez‐Backhaus, M.; Gómez-Ferrer, Á.; Collado, A.; Rubio, Luis; Molina, A.; Vanaclocha, Mercedes; Sala, Danila Cristina Paquier; Löpez‐Guerrero, José Antonio

doi:10.1016/j.acuro.2016.10.008

Cited by 10 publications

(7 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mechanistic studies illustrated that it might regulate androgen receptor (AR) signaling to improve PCa cell survival. In addition, PCA3 level was not increased in prostatic inflammatory or hyperplasia, and its level was not associated with prostatic volume 8. Moreover, PCA3 expression level was correlated with biopsy outcome and PCa progression (eg, tumor grade and Gleason score) 8.…”

Section: Introductionmentioning

confidence: 89%

“…Eight hundred thirty-eight men with a normal DRE result and PSA ≥3 ng/mL had the PCA3 test done. In PCA3 positive (n=301) and PCA3 negative (n=256) groups, 40.9% and 14.7% PCa were identified, respectively ( P <0.001) 10. The false-negative cases for high-grade PCa would be reduced by 37.1% 10.…”

Section: Introductionmentioning

confidence: 92%

“…In addition, PCA3 level was not increased in prostatic inflammatory or hyperplasia, and its level was not associated with prostatic volume 8. Moreover, PCA3 expression level was correlated with biopsy outcome and PCa progression (eg, tumor grade and Gleason score) 8. In 2012, FDA approved that the PCA3 expression level was detected as a diagnostic test for PCa in the cases with a prior negative biopsy 9.…”

Section: Introductionmentioning

confidence: 99%

“…Patients with PCA3 score <25 were 4.56-fold more likely to have a negative biopsy than men with its score >25 9. In 2017, PCA3 performance was compared with the European Randomized Study of Screening for Prostate Cancer risk calculator model 3 in an opportunistic screening 10. Eight hundred thirty-eight men with a normal DRE result and PSA ≥3 ng/mL had the PCA3 test done.…”

Section: Introductionmentioning

confidence: 99%

“…In PCA3 positive (n=301) and PCA3 negative (n=256) groups, 40.9% and 14.7% PCa were identified, respectively ( P <0.001) 10. The false-negative cases for high-grade PCa would be reduced by 37.1% 10. Although the PCA3 screening might have potential as a second-line test used in men with high PSA levels, the prognostic value of PCA3 score remained controversial because the cutoff value was debated.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

<p>Research status and progress of the RNA or protein biomarkers for prostate cancer</p>

Song¹,

Chen²,

Song³

2019

OTT

View full text Add to dashboard Cite

Prostate cancer is a kind of male malignancy. Recently, a large number of studies have reported many potential biomarkers for the diagnosis and prognosis of prostate cancer. In this literature review, we have collected a number of potential biomarkers for prostate cancer reported in the last 5 years. Among them, some are undergoing Phase III clinical trials, and others have been approved by the US Food and Drug Administration. However, most are still in the period of basic research. The review will contribute to future research to find the biomarkers to guide clinicians to make personalized treatment decisions for each prostate cancer patient.

show abstract

Section: Introductionmentioning

confidence: 89%

Section: Introductionmentioning

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

<p>Research status and progress of the RNA or protein biomarkers for prostate cancer</p>

Song¹,

Chen²,

Song³

2019

OTT

View full text Add to dashboard Cite

show abstract

Validation of a 2‐gene mRNA urine test for the detection of ≥GG2 prostate cancer in an opportunistic screening population

et al. 2020

View full text Add to dashboard Cite

Background: A 2-gene urine-based molecular test that targets messenger RNAs known to be overexpressed in aggressive prostate cancer (PCa) has been described as a helpful method for detecting clinically significant prostate cancer (grade group [GG] ≥2). We performed an external validation of this test in men undergoing initial prostate biopsy (Bx) within a Spanish opportunistic screening scenario. Methods:We analyzed archived samples from 492 men who underwent prostate Bx in an opportunistic screening scenario, with prostate-specific antigen (PSA) 3 to 10 ng/mL and/or suspicious digital rectal exploration (DRE) and without previous multi-parametric magnetic resonance imaging (mpMRI). Urinary biomarker measurements were combined with clinical risk factors to determine a risk score, and accuracy for GG ≥ 2 PCa detection was compared with PCA3, European randomized screening in prostate cancer (ERSPC), and prostate biopsy collaborative group (PBCG) risk calculators in a validation workup that included calibration, discrimination, and clinical utility analysis.Results: In our cohort, the detection rates for GG1 and GG ≥ 2 PCa were 20.3% and 14.0%, respectively. The median PSA level was 3.9 ng/mL and 13.4% of subjects had suspicious DRE findings. The median risk score for men with GG ≥ 2 PCa was 21 (interquartile range: 14-28), significantly higher than benign+GG1 PCa (10, 6-18), P < .001, achieving the highest area under the curve among the models tested, 0.749 (95% confidence interval: 0.690-0.807). The urine test was well-calibrated, while ERSPC showed a slight underestimation and PBCG a slight overestimation of risk.Assuming a GG2 non-detection rate of 11% without using mpMRI, use of the urinary biomarker-based clinical model could have helped avoid 37.2% of excess biopsies Jose Rubio-Briones and Ángel Borque-Fernando contributed equally to this study. SUPPORTING INFORMATIONAdditional supporting information may be found online in the Supporting Information section. How to cite this article: Rubio-Briones J, Borque-Fernando A, Esteban LM, et al. Validation of a 2-gene mRNA urine test for the detection of ≥GG2 prostate cancer in an opportunistic screening population. The Prostate. 2020;80:500-507.

show abstract

Controversia en el uso del PCA3 en América Latina y el Caribe

Saldaña-Gallo¹,

Grandez-Urbina²

2018

Actas Urológicas Españolas

View full text Add to dashboard Cite

PCA3 como biomarcador de segunda línea en un programa de screening oportunista prospectivo, aleatorizado y controlado

Cited by 10 publications

References 38 publications

<p>Research status and progress of the RNA or protein biomarkers for prostate cancer</p>

<p>Research status and progress of the RNA or protein biomarkers for prostate cancer</p>

Validation of a 2‐gene mRNA urine test for the detection of ≥GG2 prostate cancer in an opportunistic screening population

Controversia en el uso del PCA3 en América Latina y el Caribe

Contact Info

Product

Resources

About